CAR-T & bispecific antibodies in second-line DLBCL
Optimizing the Current and Future Management of Relapsed/Refractory DiffuseПодробнее
Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of LymphomaПодробнее
How to best manage first relapse in DLBCL outside of CAR-TПодробнее
CAR-T Therapy and Stem cell transplant in Lymphoma patients: Current treatment landscapeПодробнее
Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCLПодробнее
Advances and unmet needs in second-line treatment of DLBCLПодробнее
The role of bispecific antibodies in the treatment landscape for R/R DLBCLПодробнее
Updated BSH guidelines for managing DLBCLПодробнее
Exploring available third-line treatment options for R/R DLBCL: CAR-T, bispecifics, ADCs & mAbsПодробнее
The use of ADCs & bispecific antibodies before and after CAR-T therapy in third-line DLBCLПодробнее
Comparing the efficacy and curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCLПодробнее
How to Treat My Non-Hodgkin Lymphoma: What are the Different Treatment Options? | The Patient StoryПодробнее
Understanding the treatment course in diffuse large b cell lymphoma (DLBCL)Подробнее
Bispecifics & CAR-T therapy in DLBCL: sequencing and selecting between these agentsПодробнее
Relapsed and Refractory Diffuse Large B-Cell LymphomaПодробнее
Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodiesПодробнее
The possibility of combining CAR-T therapy and bispecific antibodies in the treatment of NHLПодробнее
How the treatment of DLBCL and FL are changing in the UKПодробнее
Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphomaПодробнее
CAR-T or stem cell transplant for second-line treatment of aggressive B-cell NHL?Подробнее
